Article Type
Changed
Tue, 11/21/2023 - 13:48

Key clinical point: Surgical removal of the primary tumor failed to prolong survival and may not be necessary in patients with de novo metastatic breast cancer (BC).

Major finding: In women with de novo metastatic BC, primary breast tumor surgery vs no surgery improved the local progression-free survival outcomes (hazard ratio [HR] 0.37; 95% CI 0.19-0.74) but not the overall survival (HR 0.93; 95% CI 0.76-1.14).

Study details: Findings are from a meta-analysis of five randomized controlled trials including 1381 patients with de novo metastatic BC, of whom 49.6% underwent primary breast tumor surgery.

Disclosures: This study did not receive any specific funding. Three authors declared having advisory roles, serving as consultants, or receiving speaker fees, consulting fees, or unrelated research grants from various sources.

Source: Villacampa G et al. Impact of primary breast surgery on overall survival of patients with de novo metastatic breast cancer: A systematic review and meta-analysis. Oncologist. 2023 (Sep 12). doi: 10.1093/oncolo/oyad266

 

 

Publications
Topics
Sections

Key clinical point: Surgical removal of the primary tumor failed to prolong survival and may not be necessary in patients with de novo metastatic breast cancer (BC).

Major finding: In women with de novo metastatic BC, primary breast tumor surgery vs no surgery improved the local progression-free survival outcomes (hazard ratio [HR] 0.37; 95% CI 0.19-0.74) but not the overall survival (HR 0.93; 95% CI 0.76-1.14).

Study details: Findings are from a meta-analysis of five randomized controlled trials including 1381 patients with de novo metastatic BC, of whom 49.6% underwent primary breast tumor surgery.

Disclosures: This study did not receive any specific funding. Three authors declared having advisory roles, serving as consultants, or receiving speaker fees, consulting fees, or unrelated research grants from various sources.

Source: Villacampa G et al. Impact of primary breast surgery on overall survival of patients with de novo metastatic breast cancer: A systematic review and meta-analysis. Oncologist. 2023 (Sep 12). doi: 10.1093/oncolo/oyad266

 

 

Key clinical point: Surgical removal of the primary tumor failed to prolong survival and may not be necessary in patients with de novo metastatic breast cancer (BC).

Major finding: In women with de novo metastatic BC, primary breast tumor surgery vs no surgery improved the local progression-free survival outcomes (hazard ratio [HR] 0.37; 95% CI 0.19-0.74) but not the overall survival (HR 0.93; 95% CI 0.76-1.14).

Study details: Findings are from a meta-analysis of five randomized controlled trials including 1381 patients with de novo metastatic BC, of whom 49.6% underwent primary breast tumor surgery.

Disclosures: This study did not receive any specific funding. Three authors declared having advisory roles, serving as consultants, or receiving speaker fees, consulting fees, or unrelated research grants from various sources.

Source: Villacampa G et al. Impact of primary breast surgery on overall survival of patients with de novo metastatic breast cancer: A systematic review and meta-analysis. Oncologist. 2023 (Sep 12). doi: 10.1093/oncolo/oyad266

 

 

Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Article Series
Clinical Edge Journal Scan, Breast Cancer November 2023
Gate On Date
Tue, 12/20/2022 - 14:15
Un-Gate On Date
Tue, 12/20/2022 - 14:15
Use ProPublica
CFC Schedule Remove Status
Tue, 12/20/2022 - 14:15
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article